Table 2.

All randomised controlled trials comprising a basal insulin analogue regimen in previously insulin-naïve patients with type 2 diabetes. Basal analogue arm baseline demographic and treatment effects, listed in rank order according to duration of diabetes. Age (mean±s.d.) or (median (quartiles)); duration of diabetes (mean±s.d.) or (median (quartiles)).

Trial	Insulin treatment		OAD treatment		Study				HbA1c (%)		Hypoglycaemia		Weight
Ref.	Prep.	Regimen	OAD	Change from baseline	Duration (weeks)	Patients (n)	Male (%)	Diabetes duration (years)	Baseline	EOT	Episodes	Definition	Change (kg)
(28)	Iglar	QD		↓	24c	53	43	5.5±2.8	8.1±1.3	7.3 (7.8, 6.7)a	3.7b,e	S/BG <54 mg/dl	+0.7±3.8
(42)	Iglar	QD		→	48c	121	48	6.5±4.9	9.4±1.2	6.9	5.0e	BG <70 mg/dl	+3.9
(34)	Iglar	QD	+Met/SU	→	16c	138	47	7.4±8.2b	9.0±1.2b	7.6	2.6e	S/BG <60 mg/dl	+3.3±4.7b
(36)	Idet	QD FBG <5.0		→	20c	122	56	7.9	8.0	6.8	7.5e	S/BG <56 mg/dl	+0.9±0.4
(38)	Iglar	QD	−SU+Met	↓	36c	55	53	8.2±5.3	8.7±0.7	7.1±0.8a,b	6.0e	S/BG <72 mg/dl	+2.8±3.5
(39)	Iglar	QD pm	+SU	↓	28c	227	58	8.2	9.1±1.0	8.1±1.3	43.0f	S/BG <75 mg/dl	+3.7±3.6
(86)	Iglar	QD	Usual/lab	→	24c	1491	52	8.4±6.4	8.9±1.5	7.5	3.7e	BG <70 mg/dl	Not given
(86)	Iglar	QD	Usual/POC	→	24c	1363	53	8.4±6.4	8.9±1.6	7.3	3.7e	BG <70 mg/dl	Not given
(87)	Iglar	QD	±Met±SU±TZD	→	26	116	66	8.4±6.4	8.5±0.7	7.3±1.1b	36.8f	BG <60 mg/dl	+3.0±3.2b
(26)	Iglar	QD		→	16d	60	57	8.4±4.9	9.2±1.3	7.3±0.1	2.4b,e	BG <54 mg/dl	+1.5±0.5
(44)	Iglar	QD		→	24c	367	55	8.4±5.6	8.6±0.9	7.0	9.2e	BG <56 mg/dl	Not given
(86)	Iglar	QD	Active/lab	→	24c	1501	49	8.6±6.4	8.9±1.6	7.5	6.0e	BG <70 mg/dl	Not given
(86)	Iglar	QD	Active/POC	→	24c	1366	50	8.7±6.4	8.8±1.5	7.3	6.0e	BG <70 mg/dl	Not given
(30)	Iglar	QD	+Met±TZD	↓	28c	116	56	8.9±4.8	9.8±1.4	7.4±1.2	0.7e	S/BG <56 mg/dl	+3.5±4.5
(21)	Idet	QD		→	52c	234	61	9.0 (6.0, 12.0)	8.4±0.8	7.6±1.0	2.3e	BG <56 mg/dl	+1.9±4.2
(36)	Idet	QD FBG <6.1		→	20c	122	64	9.0	7.9	7.0	5.3e	S/BG <56 mg/dl	+0.1±0.4
(88)	Iglar	QD		→	44	204	52	9.0±6.8	8.7±1.0	7.0±0.7	4.2e	BG <60 mg/dl	+3.0±4.3
(29)	Iglar	QD	+Met	↓	16d	105	63b	9.0±6.6b	8.7±1.3	7.8±1.1	4.8b,e	S/BG <63 mg/dl	+1.6±1.0
(39)	Iglar	QD am	+SU	↓	28c	236	52	9.0	9.1±1.0	7.8±1.2	56.0f	S/BG <75 mg/dl	+3.9±4.5
(47)	Iglar	QD	+Met	↓	36	61	62	9.0±7.8b	9.5±0.8b	7.1±0.8b	5.4e	BG <72 mg/dl	+3.5±5.5b
(45)	Idet	QD/BID		→	52c	291	57	9.1±6.1	8.6±0.8	7.2±1.7b	2.9e	BG <56 mg/dl	+3.0±6.8b
(45)	Iglar	QD		→	52c	291	59	9.1±6.4	8.6±0.8	7.1±1.7b	2.9e	BG <56 mg/dl	+3.9±6.8b
(89)	Iglar	QD		→	26	260	57	9.2±5.7	8.3±1.0	7.1±1.6a,b	6.3e	S/BG <60 mg/dl	+1.8±3.0a,b
(24)	Iglar	QD		→	24c	1046	53	9.3±5.9	9.0±1.2	7.3±1.1	23.1e	S/BG <70 mg/dl	+2.5±4.0
(46)	Iglar	QD am	+SU	↓	24c	312	55	9.5±6.1	8.8±1.0	7.2±1.1	43.1f	S/BG <50 mg/dl	+2.1
(23)	Iglar	QD	+Met+SU	?	26c	238	41	9.5±6.1	8.5±1.1	7.3	4.8e	S/BG <56 mg/dl	+1.7
(41)	Idet	BID		→	24c	227	49	9.6±6.6	8.6±0.8	6.8	3.7e	BG <54 mg/dl	+1.2
(27)	Iglar	QD	+SU±Met	→	24	177	61	9.9±7.3	8.8±1.0	7.2±0.9	4.1e	BG <60 mg/dl	+1.4±3.4
(35)	Iglar	QD		→	49c	103	55	10.0±6.2	7.6±0.3	6.8±0.7	55.3f	Symptoms	+0.9±2.9
(25)	Iglar	QD	+SU	↓	28c	127	49	10.2±6.2	8.9±1.3	7.9±1.3	9.0f	BG <56 mg/dl	+1.5
(37)	Iglar	QD	+SU	↓	24c	231	43	10.3±6.4	9.1±1.0	7.7±1.3	5.0e	Symptoms	Not given
(46)	Iglar	QD	+SU	↓	24c	312	55	10.3±6.8	8.8±1.0	7.2±1.1	38.4f	S/BG <50 mg/dl	+1.8
(43)	Idet	QD am		→	20c	165	59	10.5±7.6	9.1±1.0	7.5±1.0	91/32g	BG <56 mg/dl	+1.2
(43)	Idet	QD pm		→	20c	169	54	10.5±7.0	8.9±1.0	7.4±0.8	82/27g	BG < 56 mg/dl	+0.7

Ref., references; Prep., Preparation; Iglar, insulin glargine; Idet, insulin detemir; QD, once daily; BID, twice daily; Met, metformin; SU, sulphonylurea; TZD, thiazoledinedione; →, unchanged; ↓, reduced; ?, unknown; BG, blood glucose; S/BG, Symptoms or BG.

^aValues obtained by digitising published figures.

^bValues obtained by calculations based on published data.

^cParallel study design.

^dCrossover study design.

^eIncidence reported as events per patient year.

^fPrevalence reported as % with at least one event.

^gPrevalence reported as number of events/number of patients.